ArticleJournal of medical biochemistry2026
Retrospective analysis of the curative effect of Kanglaite injection on pancreatic cancer.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To systematically evaluate the curative effect of Kanglaite Injection (KLT) in treating pancreatic cancer (PC) by retrospective analysis. Methods: The clinical data of 172 patients with pancreatic cancer were analyzed, and the therapeutic effect, survival time and tumour markers of patients receiving Kanglaite injection combined with conventional chemotherapy were compared with those receiving conventional chemotherapy. Results: The univariate results showed that the two groups had WBC, LY#, MO#, NE#, ALB, FFA, CA199, CA125 in age, sex, tumour site, stage of pancreatic cancer, radiotherapy and metastasis, and laboratory indexes. Multivariate analysis showed that using KLT in pancreatic cancer patients was significantly related to gender and survival outcome, and KLT could prolong the survival of PC patients. In addition, the Chi-square test showed that patients with KLT could reduce the influence on monocyte count and albumin abnormality, which suggested that patients with KLT could reduce adverse reactions. Conclusions: Kanglaite injection combined with conventional radiotherapy and chemotherapy plays a significant role in improving therapeutic effect, immune function, and prolonging survival expression, and it will not increase the incidence of severe adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.